Historical pattern for $QQQ: Regular session volume routinely overrides thin pre-market moves. The regular hours low is below the pre-market low on ~58% of days overall, but when the broader trend is up and the gap isn't huge, the session frequently recovers and trades back above the pre-market low (and often the previous close) by the end of the day or even by midday.
$abbv still actively looking for obesity assets, and as expected, is positioning China as one of its key strategic focus in terms of external innovation $vktx $gpcr $lly $nvo $pfe
I'm experimenting with 5-MeO-DMT because it may be most underrated longevity molecule no one is talking about.
+ Accelerated neurogenesis: a single dose more than doubled brain cell proliferation and neuronal regeneration in the hippocampus within 12 hours, alongside measurable increases in synaptic density and firing frequency in rodent models.
+ Proteomic reorganization: in human cerebral organoids, 5-MeO-DMT triggers rapid proteomic shifts favoring cellular reorganization and synapse formation. Early evidence of structural brain renewal at the molecular level.
+ Default Mode Network reset: The DMN calcifies with age locking us into rigid, repetitive patterns of thought. 5-MeO-DMT disrupts these patterns, restoring bottom up connectivity between sensory and creative brain regions. A forced return to neurological flexibility and youthfulness.
+ Systemic anti-inflammation: suppresses pro-inflammatory cytokines (IL-1β, IL-6, TNF-alpha) while upregulating IL-10, the anti-inflammatory signal. Mediated through the Sigma-1 receptor, suggesting a mechanism distinct from other psychedelics.
@StockSavvyShay@VanquishTrader The CEO did state deployable capital towards M&A can range from $20 billion to over $40 billion in 2026, but I have not yet seen any biotech buyout over 300% premium
@RNAiAnalyst i think the logic makes sense in almost any other TA, but obesity is quite different. time to market can be the decisive factor here if an MNC is considering to enter this field.
Furthermore, the time window to fill LOE gaps between 2028-2032 is also a crucial factor
@CapitalShipyard@A_May_MD if you have RedNote or other Chinese social media accounts, you can look up mazdutide, Innovent, and its pivotal studies, and see for yourself
@A_May_MD You know obesity trial conductors in China give out free gym memberships to particioants in the Tx arm and McDonald’s gift cards to ppl on placebo
$nvo cagrisema probably won’t even outsell semaglutide’s peak. LOE approaching. Only shot is to bet big on a late stage contender. Not ao many options $vktx $lly $gpcr